A citation-based method for searching scientific literature


List of co-cited articles
1351 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
166
50

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Steve Edelman, Satish Garg, Juan Frias, David Maggs, Yan Wang, Bei Zhang, Susan Strobel, Karen Lutz, Orville Kolterman. Diabetes Care 2006
92
52

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Priscilla A Hollander, Philip Levy, Mark S Fineman, David G Maggs, Larry Z Shen, Susan A Strobel, Christian Weyer, Orville G Kolterman. Diabetes Care 2003
188
30


Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
Matthew Riddle, Juan Frias, Bei Zhang, Holly Maier, Carl Brown, Karen Lutz, Orville Kolterman. Diabetes Care 2007
65
29

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
86
22

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
172
19


Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
116
18

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Christian Weyer, Alan Gottlieb, Dennis D Kim, Karen Lutz, Sherwyn Schwartz, Maria Gutierrez, Yan Wang, James A Ruggles, Orville G Kolterman, David G Maggs. Diabetes Care 2003
58
29

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
107
17

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
Robert E Ratner, Laura L Want, Mark S Fineman, Maggie J Velte, James A Ruggles, Alan Gottlieb, Christian Weyer, Orville G Kolterman. Diabetes Technol Ther 2002
100
15

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
I Chapman, B Parker, S Doran, C Feinle-Bisset, J Wishart, S Strobel, Y Wang, C Burns, C Lush, C Weyer,[...]. Diabetologia 2005
118
15

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.
Steve R Smith, Louis J Aronne, Colleen M Burns, Nicole C Kesty, Amy E Halseth, Christian Weyer. Diabetes Care 2008
86
17

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
R Ratner, F Whitehouse, M S Fineman, S Strobel, L Shen, D G Maggs, O G Kolterman, C Weyer. Exp Clin Endocrinol Diabetes 2005
35
42

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.
Louis Aronne, Ken Fujioka, Vanita Aroda, Kim Chen, Amy Halseth, Nicole C Kesty, Colleen Burns, Cameron W Lush, Christian Weyer. J Clin Endocrinol Metab 2007
95
15

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
M S Fineman, J E Koda, L Z Shen, S A Strobel, D G Maggs, C Weyer, O G Kolterman. Metabolism 2002
79
18

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
15

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
61
24

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
136
15

Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
David G Marrero, John Crean, Bei Zhang, Terrie Kellmeyer, Maurice Gloster, Kathrin Herrmann, Richard Rubin, Naomi Fineberg, Orville Kolterman. Diabetes Care 2007
30
46

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
Søren Søgaard Lund, Lise Tarnow, Anne Sofie Astrup, Peter Hovind, Peter Karl Jacobsen, Amra Ciric Alibegovic, Ida Parving, Lotte Pietraszek, Merete Frandsen, Peter Rossing,[...]. PLoS One 2008
52
26


Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
14

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
89
15

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
B Nyholm, L Orskov, K Y Hove, C H Gravholt, N Møller, K G Alberti, C Moyses, O Kolterman, O Schmitz. Metabolism 1999
73
17


Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
48
27

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
62
20

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
M F Kong, P King, I A Macdonald, T A Stubbs, A C Perkins, P E Blackshaw, C Moyses, R B Tattersall. Diabetologia 1997
84
14

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
791
12

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
972
12

Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.
G J Cooper, A C Willis, A Clark, R C Turner, R B Sim, K B Reid. Proc Natl Acad Sci U S A 1987
813
12

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
114
12

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
689
12

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C Knowler, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, David M Nathan. N Engl J Med 2002
11

Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.
M Samsom, L A Szarka, M Camilleri, A Vella, A R Zinsmeister, R A Rizza. Am J Physiol Gastrointest Liver Physiol 2000
81
13

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies.
Jonathan D Roth, Barbara L Roland, Rebecca L Cole, James L Trevaskis, Christian Weyer, Joy E Koda, Christen M Anderson, David G Parkes, Alain D Baron. Proc Natl Acad Sci U S A 2008
271
11

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
11

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
84
13


Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation.
P Westermark, U Engström, K H Johnson, G T Westermark, C Betsholtz. Proc Natl Acad Sci U S A 1990
507
11

Amylin concentrations and glucose control.
J E Koda, M Fineman, T J Rink, G E Dailey, D B Muchmore, L G Linarelli. Lancet 1992
98
11

Temporal patterns in overweight and obesity in Type 1 diabetes.
B Conway, R G Miller, T Costacou, L Fried, S Kelsey, R W Evans, T J Orchard. Diabet Med 2010
162
11

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
96
11

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
63
17

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
84
13

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
96
11

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.
Steven R Smith, John E Blundell, Colleen Burns, Cinzia Ellero, Brock E Schroeder, Nicole C Kesty, Kim S Chen, Amy E Halseth, Cameron W Lush, Christian Weyer. Am J Physiol Endocrinol Metab 2007
77
12

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
Matthew Riddle, Richard Pencek, Supoat Charenkavanich, Karen Lutz, Ken Wilhelm, Lisa Porter. Diabetes Care 2009
38
26


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.